Absorption, distribution, metabolism, and excretion properties of two unformulated model short interfering RNA (siRNAs) were determined using a single internal [ 3 H]-radiolabeling procedure, in which the full-length oligonucleotides were radiolabeled by Br/ 3 H -exchange. Tissue distribution, excretion, and mass balance of radioactivity were investigated in male CD-1 mice after a single intravenous administration of the [ 3 H]siRNAs, at a target dose level of 5 mg/kg. Quantitative whole-body autoradiography and liquid scintillation counting techniques were used to determine tissue distribution. Radiochromatogram profiles were determined in plasma, tissue extracts, and urine. Metabolites were separated by liquid chromatography and identified by radiodetection and highresolution accurate mass spectrometry. In general, there was little difference in the distribution of total radiolabeled components after administration of the two unformulated [ 3 H]siRNAs. The radioactivity was rapidly and widely distributed throughout the body and remained detectable in all tissues investigated at later time points (24 and 48 hours for [ 3 H]MRP4 (multidrug resistance protein isoform 4) and [ 3 H]SSB (Sjögren Syndrome antigen B) siRNA, respectively). After an initial rapid decrease, concentrations of total radiolabeled components in dried blood decreased at a much slower rate. A nearly complete mass balance was obtained for the [ 3 H]SSB siRNA, and renal excretion was the main route of elimination (38%). The metabolism of the two model siRNAs was rapid and extensive. Five minutes after administration, no parent compound could be detected in plasma. Instead, radiolabeled nucleosides resulting from nuclease hydrolysis were observed. In the metabolism profiles obtained from various tissues, only radiolabeled nucleosides were found, suggesting that siRNAs are rapidly metabolized and that the distribution pattern of total radiolabeled components can be ascribed to small molecular weight metabolites.
Introduction
Over the past decade, the pharmaceutical industry has shown a significant interest in RNA interference therapeutics, particularly for the potential of small interfering RNAs (siRNA) as triggers of this endogenous mechanism, which theoretically can silence or slow the production of any protein. This new therapeutic potential would offer an innovative alternative to treat human diseases that may not be treatable with traditional approaches. Understanding siRNA biodistribution and biostability is essential for their development as therapeutics. Although a variety of nonisotopic labeling techniques exist (e.g., bioluminescence and fluorescence) (Bogdanov, 2008; Moore and Medarova, 2009 ), the use of 3 H-radiolabeled oligonucleotides to perform (pre)-clinical in vitro and/or in vivo studies offers a distinct advantage of avoiding chemical and structural modifications.
Several preclinical studies have been reported that used radiolabeled siRNAs. Nevertheless, the labeling methods applied in those studies had potential drawbacks. Typically, siRNAs were 3 H-labeled at chemically unstable positions (Mook et al., 2007; Sonoke et al., 2008; Mook et al., 2010) or at problematic sites at the end of the oligonucleotide, such as by addition of a [ 32 P]-phosphate group to the 59-end (Beale et al., 2003; Khan et al., 2004; Ocker et al., 2005; Yanagihara et al., 2006; Malek et al., 2008; Gao et al., 2009; Malek et al., 2009) . Endlabeling of siRNAs is not optimal because of the readily cleavable end from the oligonucleotide in vivo and the loss of label to follow the distribution.
Alternatively, introduction of radioactive isotopes, such as fluorine-18 (Viel et al., 2008; Hatanaka et al., 2010) , copper-64 (Bartlett et al., 2007; Mudd et al., 2010) , technetium-99m (Kang et al., 2010 ), indium-111 (van de Water et al., 2006 Merkel et al., 2009a,b) , or iodine-125 (Braasch et al., 2004) were also tested. The incorporation of these isotopes often required conjugation with linkers and/or complexation methods. The possibility for noninvasive imaging techniques is a clear advantage of using these isotopes ( 18 F, 64 Cu, 99m Tc, 111 In, and 125 I), which is not feasible for negative beta emitters ( 3 H, 14 C, 32 P, and 35 S), where only invasive techniques, such as scintillation counting or autoradiography, have to be used. Overall, drug candidates with attached pendant groups containing complexed isotopes are often assumed to not alter the reactivity or metabolism of the molecules. However, this labeling approach has previously been shown to influence the pharmacodynamic and pharmacokinetic behavior of large molecules, such as for proteins by Swart et al. (1996) . Furthermore, biostability of the siRNAs was not considered for the majority of those studies, and the intactness of the oligonucleotides is not understood. In fact, it is difficult to draw meaningful conclusions on whether the observed distribution of radioactivity represents the parent compound, metabolites, or simply the free radiolabel.
For our work, a method for labeling siRNAs with tritium at a single internal nucleotide position (uridine or 2´-O-methyluridine) was applied (Christensen et al., 2012) . The method is thought to eliminate the previously described issues and, therefore, provides a suitable research tool for absorption, distribution, metabolism, and excretion (ADME) studies of siRNAs.
With other siRNA ADME studies using randomly labeled oligonucleotides, we here present results obtained using single internal 3 H-radiolabeled siRNAs. The tritium was placed in a chemically stable and predetermined internal position by our novel radiolabeling procedure. The objective of the present studies were to assess the ADME properties of two [ 3 H]siRNAs after intravenous administration to CD-1 mice. There was little difference in the distribution of the two [ 3 H]siRNAs tested, and renal excretion was the major route of elimination. In general, unformulated siRNAs with modest chemical modifications are considered to be metabolized rapidly in vivo (Morrissey et al., 2005) . This correlates well with our observations. Complete degradation of the guide strand to radiolabeled nucleosides was observed within 5 minutes after administration in plasma.
Materials and Methods

Test Compounds and Radiolabeling of siRNAs
The ADME properties of two unformulated siRNAs were studied in mice. For this purpose, the siRNAs were internally labeled with tritium according to procedures previously described (Christensen et al., 2012) . The MRP4 (multidrug resistance protein isoform 4) siRNA targets the transporter protein, MRP4, which is expressed in the brush-border membrane of the rat kidney. The second siRNA, the SSB (Sjögren Syndrome antigen B) siRNA, targets the ubiquitous gene, SSB. The 21mer double-stranded sequences for the MRP4 and SSB siRNAs were 59-ACAGCUCCU 9 GACACCUCUCdTdT-39 and 59-GAGAGGUGUCAGGAGCUGUdTdT-39 for the MRP4 guide and passenger strand, respectively, and 59-UuAcAUu 7 AAAGUCUGUUGUuu-39 and 59-AcAAcAGAcuuuAAuGuAAuu-39 for the SSB guide and passenger strand, respectively. The MRP4 siRNA was slightly modified by dTdT overhangs [dT (2´deoxy thymidine)], whereas the SSB siRNA was stabilized via selected incorporation of 2´-O-methyl pyrimidines [u (2´OMe uridine) and c (2´OMe cytidine)] throughout the sequences. Both siRNAs were uniquely 3 H-radiolabeled in the guide strands. The tritium atom was incorporated into the chemically stable C5 position of a predetermined uridine or 2´-O-methyluridine. The specific radioactivities of [ 3 H]MRP4 and [ 3 H]SSB siRNAs were 5.25 and 6.99 MBq/mg, respectively. Both siRNAs had a radiochemical purity of 74% by ion pair reverse phased-high-performance liquid chromatography (HPLC).
In Vivo Experiments
The animal studies were approved by Animal Care and Use Committees of the Kanton, Basel, Switzerland. Male albino CD-1 mice (Charles River France, L'Arbresle, France; weight, 26-32 g; age, 8-10 weeks) received an intravenous bolus injection in the vena saphena of either 5 mg/kg [ 3 H]MRP4 siRNA or 5 mg/kg [ 3 H]SSB siRNA in 0.9% sodium chloride under a light inhalation anesthesia by isoflurane. The radioactive dose ranged from 26.3 to 35.0 MBq/kg for MRP4 and SSB siRNAs, respectively. After administration, blood samples were collected from either vena saphena (opposite leg than used for administration) or vena cava (for end points) in EDTA-containing tubes at 0.083, 0.5, 1, 2, 4, 8, 24, and 48 hours after administration (no 8-and 48-hour time points for MRP4 siRNA). From each end point, tissues were collected and an aliquot of the blood sample was processed immediately to plasma by centrifugation at 3000g for 10 minutes at 4°C. A small aliquot was taken for total radioactivity detection, and the remainder material was snap frozen and stored at 280°C until further analysis.
Selected animals were housed in metabolic cages for urine and fecal sample collection, allowing determination of the route of excretion and the mass balance. Quantitative whole-body autoradiography (QWBA) was performed at 10, 30, and 60 minutes and 2 and 24 hours for MRP4 siRNA and at 10 and 60 minutes and 2, 24, and 48 hours for SSB siRNA. The use of animals was minimalized during these studies (11-13 mice for each siRNA; i.e., every mouse contributed to at least two types of experiments), allowing a good characterization of its pharmacokinetic properties, mass balance, routes of excretion, metabolism profiles, and tissue distribution.
In Vitro Experiments
To support the in vivo metabolism studies, in vitro incubations with both [ 3 H]siRNAs in CD-1 mouse serum (mixed sex; SeraLab, West Sussex, UK) were performed at a concentration of 25 mM (;45 KBq/ml). The mixtures were incubated at 37°C in a thermo mixer (Thermomixer comfort 5355; Eppendorf, Hamburg, Germany) for 5, 30, and 60 minutes and for 2, 4, 8, and 24 hours under gentle mixing. At the respective time points, 200-ml aliquots were mixed with an equal aliquot of Phenomenex lysis-loading buffer [containing 10 mM tris(2-carboxyethyl)phosphine; Phenomenex, Torrance, CA] and briefly vortexed. Samples were stored at 280°C until further analysis. Additional in vitro metabolic studies were performed for SSB siRNA at 1 and 5 mM under the same experimental conditions. The radiochemical purities of [ 3 H]MRP4 and [ 3 H]SSB siRNAs used for in vitro experiments were 72 and 88%, respectively.
Analytical Methods
Radiometric Analysis. Radioactive signals in the different matrices were quantified by liquid scintillation counting with use of Liquid Scintillation Systems 2500 TR from Packard Co. (Meriden, CT). For quench correction, an external standard ratio method was used. Quench correction curves were established using sealed standards (Packard). Background values were prepared for each batch of samples according to the respective matrix. The limit of detection was defined as 1.8 times the background value. All determinations of radioactivity were conducted in weighed samples. To determine possible formation of tritiated water, samples were analyzed twice: direct measurements of radioactivity and after drying of the sample (at 37°C for at least 12 hours). Dried or nondried plasma and urine samples were mixed with scintillation cocktail directly, whereas whole blood and fecal samples were solubilized before radioactivity analysis. Measured radioactivity for blood, plasma, and tissue samples was converted into concentrations (mol equivalents per volume or gram), considering the specific radioactivity and assuming a matrix density of 1 g/ml.
Tritiated Water. The determination of tritiated water was based on blood and plasma data. The following assumptions were considered. First, radioactivity was measured in nondried blood/plasma and in dried blood/plasma. The difference between the nondried and dried sample was ascribed to tritiated water. Second, the derived concentration of tritiated water in the respective matrix equals the concentration in the body water. Therefore, the tritiated water concentrations in blood were corrected by the blood cell content (92.5% of blood was expected to be water). Third, the elimination half-life (T 1/2 ) of water in the mouse was 27.1 hours (Richmond et al., 1962) , and the body water was 72.5% (Davies and Morris, 1993) of body weight. For the calculation, the concentration-time course of tritiated water in blood and plasma was analyzed by the deconvolution method given in Phoenix WinNonlin software (version 6.1.0.173; Pharsight Corp., Mountain View, CA). As input parameter for the deconvolution, the elimination rate constant of water and the reciprocal value for body water, derived from the actual body weight for the mice, were used.
QWBA. Mice were sacrificed by deep isoflurane inhalation. After deep anesthesia, blood for radioactivity determination by liquid scintillation counting was collected by vena saphena (the other leg than the one used for administration). The animals were then submerged in n-hexane/dry ice at 270°C for approximately 30 minutes. The carcasses were stored at 218°C, and all subsequent procedures were performed at temperatures below 220°C to minimize diffusion of radiolabeled materials into thawed tissues. Sections were prepared as follows. in brief, 40-mm-thick lengthwise dehydrated whole-body sections were prepared and exposed to Fuji BAS III imaging plates (FujiFilm, Tokyo, Japan) in a lead-shielded box at room temperature for two weeks and then scanned in a Fuji BAS 5000 phosphor imager (FujiFilm) at a 50-mm scanning step. The concentrations of total radiolabeled components in the tissues were determined by comparative densitometry and digital analysis of the autoradiogram; blood samples of known concentrations of total radiolabeled components processed under the same conditions were used as calibrators.
Nomenclature and Assignment of the Metabolites
Metabolites that were clearly identified-for example, by chromatographic retention time and/or mass spectral information-are named according to the origin of the metabolite: ASx for guide strand, Sx for passenger strand, or Mx for monomer-related metabolites (x being a positive integer). Furthermore, if not stated otherwise, the metabolite is a cleavage product with no phosphate. A phosphate on the cleavage product is designated by a P, and a cyclic phosphate is designated as cycP (e.g., AS4cycP). In some cases, a peak contains more than one metabolite. The percentage of the minor metabolite, based on mass spectrometry responses making that peak, is given. Pronounced but uncharacterized peaks in radiochromatograms (e.g., because of their abundance) are named as Px (x representing the approximate retention time).
Structural Elucidation of Oligonucleotide Metabolites
The structural characterizations of the parent and metabolites were done using liquid chromatography-mass spectrometry. An HPLC method under denaturing conditions was used for profiling the parent guide (and passenger) strand and oligonucleotide metabolites (LC-method 1). For smaller and more polar metabolites, which showed no retention on the HPLC method, an ultra high-performance liquid chromatography (UHPLC) method was used (LCmethod 2). Mass spectrometric data were obtained using a LTQ-Orbitrap (Thermo Fisher Scientific, Waltham, MA) in electrospray-negative or -positive mode. The radiochromatogram profiles were analyzed and identified with off-line radioactivity analysis. Metabolites were identified in each profile by mass spectrometry (MS) and/or corresponding peaks in the radiochromatogram versus a control sample. Full mass spectra were acquired for the parent compound and each metabolite. An MS spectrum of each peak gave a range of charged species up to [M-13H] 13-, each with a typical multiply charged ion envelope.
The spectra were deconvoluted to give the accurate mass of the metabolites, which were compared with the corresponding theoretical masses. The exact mass calculation was performed using the first isotopic ion of the major multiply-charged ion using the following formula: Exact mass = (M first isotopic ion Â n) + n Â H, (n = charge state of the selected ion). ProMass deconvolution software (version 2.5; Novatia, Monmouth Junction, NJ) for Thermo instruments was applied to help with metabolite identification (Zou et al., 2008) .
Sample Preparation of Matrices for Metabolite Profiling
For metabolite profiling of plasma and serum, the oligonucleotides were extracted and isolated using Clarity OTX, weak anion exchange solid phase extraction cartridges from Phenomenex, according to the manufacturer's instructions. Because low and high molecular weight materials were expected, the wash fraction of the solid phase extraction cartridge was analyzed by LCmethod 2 (low molecular weight material), whereas the higher molecular weight metabolites were collected in the elution fraction and analyzed using LC-method 1. For metabolic profiling of urine, a precipitation method was performed before analysis with use of two volumes of acetonitrile. The mixture was vortexed and centrifuged at 17,530g for 15 minutes at 4°C (Beckman GS-15R). The supernatant was recovered and concentrated to near dryness with use of an Eppendorf concentrator 5301 at 30°C and reconstituted to about 50 ml with water.
Tissue samples were homogenized using a CryoPrep system from Covaris (Woburn, MA). Equal volumes of water (by weight) were added to the pulverized tissues, and the homogenates were extracted with 3 volumes of acetonitrile overnight at 4°C in a thermo mixer (Thermomixer comfort 5355) under agitation (750 rpm). The samples were then centrifuged at 4°C, 20,000g for 20 minutes (Sigma 3K30; Sigma-Aldrich, Osterode am Harz, Germany). The supernatants recovered and concentrated under a nitrogen flow to approximately the initial volume of water, and up to 40 ml of sample was injected on the LC-systems. All extraction recoveries of radioactivity of all the sample extraction procedures described were bove 85%.
HPLC-MS-Radiometry (RA) Metabolite Identification of Oligonucleotide Metabolites (LC-Method 1) Selected plasma, urine, and tissue samples were analyzed for metabolite identification with use of ion pairing reverse phase HPLC-MS-RA. Separation was accomplished using an HPLC system from Agilent Technologies (Santa Clara, CA), 1100 Series equipped with a binary capillary pump, including a degasser, an autosampler, a column oven, and a diode array detector. The operating software monitoring the HPLC system was LC/MSD Chemstation, version B.04.02 (Agilent Technologies). Ten-microliter samples were injected on a reverse phase C18 column (150 Â 2.1 mm; 3.5 mm particles; Waters XBridge Shield; Waters, Milford, MA) equipped with a guard column (10 Â 2.1 mm; 3.5 mm particles; Waters XBridge). The column was maintained at 70°C (denaturing conditions), and the flow rate on the column was 0.25 ml/min. Eluent A consisted of 1.6 mM triethylamine and 100 mM hexafluoroisopropanol (pH ;7.5), and eluent B consisted of 1.6 mM triethylamine and 100 mM hexafluoroisopropanol in 40% methanol. The following gradient was applied: 0% B for 109 → 2.5% B/min → 50% B after 209 → 450% B/min → 95% B after 0.19 → 95% B for 4.99 → -950% B/min → 0% B after 0.19→ 0% B for 4.99. After elution from the column, the effluent was split. Approximately 20 ml was directed to the MS, and the remaining flow was monitored using a diode array detector at l of 260 nm and collected into 96-well Luma plates with use of a fraction collector (Gilson FC204; 4.2 seconds fraction size, collect from 0-27 minutes; Gilson, Middleton, WI). To help with the fraction collection, a make-up flow composed of mobile phase B was used (Jasco pump, PU-980, 0.25 ml/min; Jasco, Essex, UK). The plates were dried using a speed-vac (AES2010 from Savant ThermoFisher, Bremen, Germany) and counted (up to 60 minutes per well, depending on the level of radioactivity) on a Packard TopCount instrument (PerkinElmer, Waltham, MA). Mass measurements were made online using a LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific) operating under Xcalibur, version 2.0, for instrument control, data acquisition, and data processing. From 0 to 40 minutes, the mass spectrometer was set to scan in ESI-negative mode with resolution set at 30,000 and an m/z window from 400 to 2000. Mass spectra were obtained using a spray voltage of 3.6 kV, a sheath gas flow of 16 (arbitrarily flow rate), a source temperature at 275°C, and a capillary and tube lens voltage of 253 and 294.3 V, respectively.
UHPLC-MS-RA Metabolite Identification of Monomer Metabolites (LC-Method 2)
Selected plasma, urine, and tissue samples were analyzed for metabolite identification with use of UHPLC-MS-RA. Separation was accomplished using a UHPLC system from Agilent Technologies: 1290 Infinity equipped with a binary capillary pump including a degasser, an autosampler, and a column oven. The operating software monitoring the UHPLC system was Chemstation, version B.04.02 (Agilent Technologies). Typically, a 10-ml sample was injected on a reverse phase C18 column (150 Â 2.1 mm; 1.7 mm particles; Waters Acquity UPLC HSS T3) with a guard Waters Acquity UPLC HSS column attached (5 Â 2.1 mm; 1.7 mm particles). The column was maintained at 30°C, and the flow rate was 0.35 ml/min. Eluent A consisted of 10 mM ammonium formate (pH adjusted to 3), and eluent B consisted of 0.1% formic acid in methanol. The gradient used was 0% B for 29 → 2.5% B/min → 20% B after 89 → 37.5% B/min → 95% B after 29 → 95% B for 39 → 95% B/min → 0% B after 0.19→ 0% B for 2.99. After elution from the column, the effluent was mixed with 0.20-0.35 ml/min of methanol or ethanol (Jasco pump, PU-980) to increase the droplets per well during fraction collection. The effluent was then split for MS and fraction collection (Gilson GX-271 operation software was Trilution LC) into 384-well Luma plates (3.0-3.2 seconds fraction size). The plates were dried using a speed-vac (AES2010 from Savant) and counted up to 20 minutes per well, depending on the level of radioactivity, with use of a Packard TopCount instrument (PerkinElmer). Mass measurements were made online with use of an LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific) operating under Xcalibur, version 2.0, for instrument control, data acquisition, and data processing. From 0 to 18 minutes, the mass spectrometer was set to scan in ESI-positive or -negative mode with resolution set at 15,000 and an m/z window from 50 to 1000. Mass spectra were obtained using a spray voltage of electrospray ionization (ESI) + /ESI -3.6/3.0 kV, a sheath gas flow of 16 (arbitrarily flow rate), a source temperature at ESI + /ESI -225/275°C, 
Pharmacokinetic Analysis
Pharmacokinetic parameters and QWBA data were calculated using Phoenix WinNonlin software (version 6.1.0.173; Pharsight Corp.), unless stated otherwise. The pharmacokinetic estimations were based on a noncompartmental analysis model. The tissue to blood C max and the area under the curve calculated to the last quantifiable concentration point (AUC last ) ratios were calculated where possible. The last area under the curve were calculated using the linear trapezoidal rule. For metabolite profiles, the peaks in the radio-chromatograms were integrated, and from the relative peak areas, the concentrations of individual radiolabeled components in plasma/serum and the amounts of individual radiolabeled components in excreta were calculated as follows:
Where C i is the plasma molar concentration of radiolabeled component (i) in plasma/serum, C RA is the plasma molar concentration of total radiolabeled components (radioactivity) in plasma, RSP is the recovery of radioactivity after sample preparation (%), RPAi is the relative peak area of radiolabeled component (i) in radiochromatogram (percentage of total area under the radiochromatogram), A i is the excreta amount of radiolabeled component (i) in excreta (urine or feces; percentage of dose), and ARA is the excreta amount of total radiolabeled components (radioactivity) in excreta (urine or feces; percentage of dose).
Results
Blood/Plasma Pharmacokinetics
After intravenous administration of [ 3 H]MRP4 or [ 3 H]SSB siRNA, the concentrations of radiolabeled components were measurable throughout the observation periods in blood and plasma (for [ 3 H]MRP4 siRNA: 24 and 4 hours after dose in blood and plasma, respectively [ Fig. 1A ], and for [ 3 H]SSB siRNA, up to 48 hours after dose in both blood and plasma [ Fig. 1B] ). The concentration of total radiolabeled components decreased in a multi-exponential manner in both matrices. After the apparent C max at 5 minutes, the radioactivity decreased rapidly with elimination half-lives below 10 minutes. Samples dried before radioactivity analysis showed, in all cases, lower levels of total radioactivity, suggesting the formation of tritiated water. Measurements of dried blood were comparable with results derived from QWBA data, as shown in Fig. 1, A and B, for [ 3 H]MRP4 and [ 3 H]SSB siRNA, respectively. Detection and quantitation of the guide strands was only feasible in the 5 minute samples. This suggests an extremely fast rate of metabolism and the early presence of degradation products in the central circulation.
Tissue Distribution and Mass Balance
After single intravenous administration of the two [ 3 H]siRNA's, the radioactivity was rapidly and widely distributed throughout the body. At the last time points after administration (24 and 48 hours for [ 3 H]MRP4 and [ 3 H]SSB siRNA, respectively), all tissues, including blood, still contained measurable radioactivity. T max was observed in most matrices at the first sampling point (10 minutes after administration). In general, the highest concentrations of total radiolabeled components (C max values) were observed in the kidney (10 minutes after administration), which were 7-8-fold higher than in blood (141 and 200 nM for [ 3 H]MRP4 and [ 3 H]SSB siRNA, respectively). In addition, high concentrations of radioactivity were determined in the salivary gland, being 2-6-fold higher than in blood. Lowest concentrations (but still above limit of quantitation) were generally those in the central nervous system. Overall, the highest exposures of total radiolabeled components were observed in kidney, salivary gland, spleen, and liver. In general, there was no notable difference in the pattern of distribution after [ 3 H]MRP4 and [ 3 H]SSB siRNA administration. Figure 1, A and B , shows concentration-time profiles of total radiolabeled components in dried blood, plasma, and selected tissues after [ 3 H]MRP4 and [ 3 H]SSB siRNA administration, respectively, and Fig. 2, A and B 
Metabolic Stability of 3 H-Label
The fraction of the administered radioactive dose after intravenous administration of [ 3 H]SSB siRNA converted to tritiated water was estimated. After administration, the percentage of administered radioactivity transformed to tritiated water increased with time in mice. The mean formation of tritiated water was estimated at 9% of the radioactive dose when considering the blood and plasma at 2 hours after administration; however, the mean value increased to 26% of the dose at 48 hours after dosing. This increase indicated that the formation of tritiated water was an ongoing process, and a mean value, considering all blood and/or plasma sample time points, could not be given. Therefore, the values derived from 48 hours were used for the mass balance calculation, because this value reflected the total formation of tritiated water most accurately.
In Vivo Metabolite Profiles in Plasma, Urine, and Tissues Plasma. No intact guide strand of either [ 3 H]siRNAs was observed after their intravenous administration in any of the analyzed plasma samples, not even 5 minutes after administration. As a result, the halflives of the parent compounds in plasma could not be determined but were clearly lower than 5 minutes for both [ 3 H]-siRNAs. The metabolites detected in plasma 5 minutes after administration included 18-13mers ( Fig. 3; for Supplemental Tables 1 and 2; Supplemental  Tables 3 and 4, respectively) . Furthermore, complete degradation to the radiolabeled nucleosides was also observed (i.e., 2´-Omethyluridine [2´OMeU] and uridine [M1]). The observed retention times in radiochromatograms of these two nucleoside metabolites corresponded with their reference substances, and the correct m/z was extracted with a mass accuracy below 5 ppm (4.67 and 4.94 ppm for 2´OMeU and M1, respectively). In addition, [ 3 H]SSB siRNA O-demethylation of the 2´-O-methyluridine-stabilized guide strand to uridine was observed within 5 minutes after administration in plasma (Fig. 4) . These observations were considered as strong indications that the guide strand of both [ 3 H]siRNAs were completely metabolized to the nucleoside level in the mouse.
description of the metabolites of [ 3 H]MRP4 and [ 3 H]SSB siRNAs, see
Urine. The mean total recovery of radiolabeled components up to 48 hours after administration of [ 3 H]SSB siRNA recovered in urine and feces was 47 and 5%, respectively. Metabolite identification in feces was not conducted because of its low representation of the dose. Intact guide strand of [ 3 H]SSB siRNA was not observed in the urine up to 48 hours after administration, which is consistent with the plasma results. Large molecular weight oligonucleotide metabolites were identified in urine up to 8 hours after administration and represented 31% of the dose for the mouse sacrificed at 24 hours. The most prominent component was a 15mer (AS7, 10% of the dose). In addition, the radiolabeled nucleoside 2´-O-methyluridine and its corresponding metabolites represented 11% of the dose in urine up to 8 hours. Both nucleosides were also detected in urine at later time points (up to 48 hours after administration), but only as minor components.
Tissues. No intact material of the guide strand or even any oligonucleotide metabolites were detected in kidney, liver, or salivary gland 10 minutes or 1 hour after administration of [ 3 H]MRP4 or [ 3 H]SSB siRNA, respectively. Only uridine (M1) was detected in selected tissues (heart, kidney, liver, small intestine, and spleen) 1 hour after administration of [ 3 H]SSB siRNA. The uridine nucleoside metabolite was also detected in kidney, liver, and salivary gland after 10 minutes after administration of [ 3 H]MRP4 siRNA. For both siRNAs, the abundance of radiolabeled uridine was the highest in kidneys, among the investigated tissues. These findings supported the results obtained from plasma and urine samples.
In Vitro Metabolite Profiles in Serum
To support metabolism identification, the degradation patterns of both [ 3 H]siRNAs were investigated via incubations at 25 mM in CD-1 mouse serum for up to 24 hours. Concentrations of the guide strands (AS) were measurable for [ 3 H]MRP4 siRNA up to 4 hours and, for [ 3 H]SSB siRNA, up to 8 hours. The half-lives of both guide strands were approximately 1.7 hours. For both [ 3 H]siRNAs, the smallest degradation products observed at 25 mM incubations were 13mers of both the guide and the passenger strands.
For both, all observed metabolites of the guide strand and passenger strand originated from intramolecular cleavages from nuclease activity at the phosphodiester linkages. Refer to Supplemental Figs. 1 and 2 for kinetic profiles and mass spectrometric data for the proposed metabolites and parent compounds of the guide and passenger strands of the [ 3 H]siRNAs. The degradation appeared to occur in a stepwise manner, leading to the consecutive formation of smaller fragments of the strands (n-1, etc.). For the [ 3 H]SSB siRNA, the degradation occurred primarily from the 39-end toward the 59-end. Most of the metabolites observed were terminal cleavage products without a phosphate, but phosphate and cyclic phosphate conjugates were also observed as terminal cleavage products (Supplemental Figs. 1 and 2) .
By performing incubations at lower concentrations (5 and 1 mM for 24 hours), the metabolism of the [ 3 H]SSB siRNA was shown to be concentration dependent. The metabolism profiles obtained at higher concentrations were different from those obtained at lower concentrations. Incubations performed at lower concentrations led to higher turnover of the [ 3 H]SSB siRNA. Furthermore, complete degradation of the guide strand to the radiolabeled nucleoside 2´OMeU was also observed in vitro after 24 hours incubation at 1 mM. This observation supports the in vivo observation that the guide strand of the [ 3 H]SSB siRNA was completely metabolized to the nucleoside level.
Discussion
Understanding siRNA biodistribution and biostability behavior is essential for their development as therapeutics. A novel 3 H-radiolabeling method of oligonucleotides (Christensen et al., 2012) was used to perform preclinical ADME studies of unformulated siRNAs. Tritiated oligonucleotides offer several advantages for ADME studies, including (1) no chemical/structural modification of the oligonucleotide ( 3 H replacing a 1 H; i.e., the reactivity and metabolism of the molecule should remain unchanged; (2) these [ 3 H]siRNAs have been proven to be both radio and chemically stable for at least 6 months at 280°C (Christensen et al., 2012) , which allows a practical time window to conduct pharmaceutical formulation and pharmacokinetic studies; (3) the 3 H-label is not released by metabolic processes from the guide strand of the siRNA until it has been extensively degraded and is likely then to be RNA interference inactive; (4) simplification of the analysis of metabolites because of the presence of a single radiolabeled site in the oligonucleotide; and (5) the method is solely dependent on the existence of a uridine or a 2´-O-methyluridine residue in the sequence. This method should be applicable to chemically modified and unmodified phosphodiester oligonucleotides. However, the observed increase in formation of tritiated water over time (26% of the dose at 48 hours after administration) remains a limitation.
To address this issue, positioning of the tritium in the C6-position of a pyrimidine, instead of the current C5-position, could improve the metabolic stability, thereby reducing the formation of tritiated water. The chemical stability of the carbon-tritium bond in the C6-position of pyrimidines is known in the literature to be more stable than the C5position (Evans et al., 1970; Noll and Mittag, 1983) . The 3 H-radiolabeling method, as used in this study, remains a powerful tool for preclinical ADME studies. The methods presented in this article could be applicable to a wide range of siRNA formulations and for providing useful perspectives for the further development of in vivo applications of siRNA as therapeutics.
This study presents a comparison of the pharmacokinetics and metabolism of two unformulated [ 3 H]siRNAs. The two siRNAs, MRP4 and SSB, differ in sequences and targets. Previously reported biodistribution studies of unformulated siRNAs generally have not focused on the biostability of the siRNA, and therefore, the intactness of the oligonucleotides is less clear. In these cases, a conclusion is difficult to draw on what extent the observed distribution of radioactivity represents the parent compound, metabolites, or simply the free radiolabel. This study reveals the in vivo fate of this class of compounds in mice.
Metabolite identification of plasma, urine, and tissue samples was conducted to elucidate the in vivo fate of the [ 3 H]siRNAs. Metabolites were separated by LC and subsequently identified by radiodetection and high-resolution accurate MS. In addition, in vitro incubations of both [ 3 H]siRNAs in CD-1 mouse serum were done to support metabolite profiling and metabolite identification. The degradation of the [ 3 H]SSB siRNA was shown to be concentration dependent. Overall, the rate of in vivo degradation for both siRNAs clearly exceeded their rate of degradation in vitro. This difference in degradation rates has also been reported by Viel et al. (2008) .
In general, there was little difference in the distribution of these two unformulated [ 3 H]siRNAs. After intravenous administration of the [ 3 H]siRNAs, the radioactivity was rapidly and widely distributed throughout the body, which was determined by QWBA in all tissues investigated up to 24 and 48 hours for the MRP4 and SSB siRNA, respectively. At early time points, the highest concentrations of radioactivity were located in the kidney. Lowest concentrations (but still above limit of quantitation) were generally those in the central nervous system. At later time points, the highest concentrations of total radiolabeled components were observed in kidney, salivary gland, spleen, and liver. Our observations that the kidney, followed by the liver, are the primary organs for distribution of radioactive components after systemic administration of unformulated [ 3 H]siRNAs are in agreement with other unformulated siRNA biodistribution studies reported in mice (Braasch et al., 2004; Ocker et al., 2005; Bartlett et al., 2007; de Wolf et al., 2007; Mook et al., 2007; Viel et al., 2008; Gao et al., 2009; Malek et al., 2009; Merkel et al., 2009a,b; Hatanaka et al., 2010; Kang et al., 2010; Mook et al., 2010; Mudd et al., 2010) .
Among the investigated tissues, the parent guide strand of either siRNAs or any oligonucleotide metabolites were not observed, even 10 minutes after administration, for the MRP4 siRNA. Nevertheless, radiolabeled nucleoside metabolites were observed for both siRNAs, including the monomer uridine (M1). In general, unformulated siRNAs with modest chemical modifications are considered to be metabolized rapidly in vivo (Morrissey et al., 2005) , which correlates well with the observations presented in this work. Complete degradation of the guide strand of either [ 3 H]siRNAs to their radiolabeled nucleosides was observed only 5 minutes after administration in plasma. In addition, within 5 minutes after administration in plasma, an O-demethylation of the radiolabeled 2Ó MeU nucleoside to uridine was also observed (Fig. 4) . Because parent guide strands of either siRNAs were not observed in plasma, intact parent compound was assumed not to be distributed in the tissues. This observation was supported by metabolite investigations in selected tissues and in urine. The radiolabeled nucleosides were also observed in vitro in serum. The extremely rapid degradation to monomers has also been observed in vivo for the comparable antisense technology with oligodeoxynucleotides, as reported by Sands et al. (1994 Sands et al. ( , 1995 .
A nearly complete mass balance was obtained for the [ 3 H]SSB siRNA at 48 hours (87%). Radiolabeled components were excreted predominantly via the urine (38%) and only to a minor extent via feces (7%). No parent compound was observed in the urine, and the recovered radioactivity was associated with both oligonucleotide and nucleoside metabolites. These findings supported the results obtained from plasma and tissue samples.
The MRP4 siRNA has previously been radiolabeled with 111 In and administered intravenously for a biodistribution study in rats by van de Water et al. (2006) . The labeling was placed using a cDTPA-chelator/ [ 111 In]-complex conjugated to an amino C7 linker at the 39-end of the guide strand of the MRP4 siRNA. This technique has some potential drawbacks: short half-life of 111 In (2.8 days), 39-endlabeling, and the effect of the chemical modification by the bulky chelator/[ 111 In]complex on the distribution and pharmacokinetics is unknown. Studies using proteins have shown that labeling by 125 I affected the pharmacokinetics, compared with the molecule labeled with carbon-14 (Swart et al., 1996) .
The siRNA labeled with either 111 In or 3 H was found to both distribute primarily to the kidneys and predominantly be excreted via the urine. As a standard of reference, the radioactivity per matrix was determined by calculating the percentage of the injected dose per gram matrix (% ID/g). The amounts of radiolabeled components in the kidneys 1 hour after injection were 1.7% and 9.3% ID/g. This, on average, was 40 and 5 times higher than that in other matrices investigated (blood, brain, intestine, liver, lung, muscle, and spleen) for the 111 In-and 3 H-labeled MRP4 siRNA, respectively. All observed matrix concentrations 1 hour after administration for the [ 3 H]siRNA were higher than those for the [ 111 In]siRNA. Furthermore, liver distribution was not observed by van de Water et al. (2006) . This discrepancy does not appear to be explained by interspecies differences (rat versus mouse), because another study in rat (and mouse) described by Viel et al. (2008) reported kidney and liver distributions in both rodents. In addition, for the [ 3 H]siRNA, significant distribution of radioactivity was observed in the salivary gland and spleen (8.9% and 2.4% ID/g, respectively). The salivary gland, contrary to the spleen (Mook et al., 2007; Mook et al., 2010) , has not before been reported as an organ of distribution of total radiolabeled components after siRNA administration.
The distribution studies indicated most likely not intact siRNA but more likely the degraded nucleosides. This was definitely the case for our model [ 3 H]siRNAs, as discussed above. Only a few of the aforementioned studies addressed this: Gao et al. (2009) by Northern blotting and Malek et al. (2009) by autoradiography on gel. By these methods, both groups discovered that almost none of the radioactivity taken up by the kidney corresponded to intact siRNA. Viel et al. (2008) studied the biostability of the parent compound in plasma by HPLC and found that the unmodified siRNA was rapidly degraded, with a half-life of approximately 3 minutes.
The observed differences in distribution and pharmacokinetics between the [ 111 In]-and [ 3 H]MRP4 siRNA may be caused by the location of the label (39-end versus internal), the radiolabeling method used ( 111 In versus 3 H), and/or interspecies differences (rat versus mouse). Overall, the 111 In-labeled MRP4 siRNA showed different distribution and pharmacokinetics, compared with the molecule labeled with 3 H.
In conclusion, the two unformulated [ 3 H]siRNAs were rapidly metabolized in vivo in the mouse. The parent guide strands of either siRNAs were not observed in any matrices (plasma, urine, and tissues). Instead, complete degradation of the siRNA occurred. The distribution of the radioactivity is therefore more associated with the distribution of radiolabeled nucleoside than that of the siRNA. Fig. 4 . Metabolite profile of [ 3 H]SSB siRNA in plasma 5 minutes after administration, indicating complete degradation to single nucleosides (analysis of saline/phosphate/EDTA wash fraction by LC-method 2).
